In addition, Terrance Gregg, DexCom’s president and CEO, also purchased 150,000 additional shares of common stock in this offering at a per share price of $3.12, which represents the last reported bid price on the NASDAQ global market of DexCom’s common stock on January 29, 2009.
The gross proceeds to DexCom, before expenses, from the sale of the shares were $48 million. Piper Jaffray & Co acted as sole manager for the offering.